Ameriprise Financial Inc. Sells 645,170 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Ameriprise Financial Inc. cut its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 97.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,326 shares of the company's stock after selling 645,170 shares during the period. Ameriprise Financial Inc.'s holdings in Perspective Therapeutics were worth $55,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of CATX. Y Intercept Hong Kong Ltd bought a new stake in shares of Perspective Therapeutics during the fourth quarter valued at about $33,000. Aigen Investment Management LP purchased a new position in shares of Perspective Therapeutics during the fourth quarter worth about $34,000. National Bank of Canada FI grew its holdings in shares of Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after purchasing an additional 10,998 shares in the last quarter. Vontobel Holding Ltd. purchased a new position in shares of Perspective Therapeutics during the fourth quarter worth about $51,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in shares of Perspective Therapeutics during the fourth quarter worth about $51,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Stock Up 6.4%

Shares of CATX stock opened at $3.32 on Friday. The stock has a fifty day moving average of $2.33 and a 200 day moving average of $2.87. Perspective Therapeutics, Inc. has a 52 week low of $1.60 and a 52 week high of $16.55.

Analyst Ratings Changes

Several brokerages have recently commented on CATX. Cantor Fitzgerald raised Perspective Therapeutics to a "strong-buy" rating in a report on Tuesday, March 4th. Wedbush reissued an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, May 13th. Royal Bank of Canada raised Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and boosted their price objective for the stock from $15.00 to $16.00 in a report on Tuesday, June 3rd. Scotiabank began coverage on Perspective Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price objective for the company. Finally, Truist Financial cut their target price on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $12.63.

Insider Buying and Selling

In other Perspective Therapeutics news, CEO Johan M. Spoor purchased 22,026 shares of the company's stock in a transaction that occurred on Friday, March 28th. The stock was bought at an average price of $2.24 per share, with a total value of $49,338.24. Following the completion of the purchase, the chief executive officer now directly owns 59,383 shares of the company's stock, valued at $133,017.92. The trade was a 58.96% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Robert F. Williamson III acquired 22,192 shares of the firm's stock in a transaction on Friday, March 28th. The stock was purchased at an average price of $2.27 per share, with a total value of $50,375.84. Following the acquisition, the director now owns 70,837 shares of the company's stock, valued at $160,799.99. This represents a 45.62% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 115,696 shares of company stock valued at $256,344 over the last quarter. 3.72% of the stock is owned by company insiders.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.